Analyst Ratings for Karyopharm Therapeutics (KPTI)
KPTI Rating Summary
KPTI Price Target Summary
- Highest: $23.00 (RBC Capital)
- Lowest: $6.00 (Leerink Partners)
- Average: $15.40
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$15.40 (+75.6%)
* Over Last 12-Mos
Rating Score: 7.1 / 10
Percentile Rank: 76%
Avg. $ Target:
$15.40 (+75.6%)
* Over Last 12-Mos
Rating Score: 7.1 / 10
Percentile Rank: 76%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/5/2026 | Cantor Fitzgerald » Updated 3/6/2026 |
Yanni Souroutzidis | New Coverage | Overweight (N/A) |
N/A (N/A) |
6.55 (8.77) |
33.89% | Details |
| 10/13/2025 | H.C. Wainwright | Robert Burns | Upgrade | Buy (Neutral) |
15.00 (N/A) |
5.50 (8.77) |
59.45% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
